Melanoma Trial, Recruiting NCT06298734 Sponsor: Fred Hutchinson Cancer Center Condition: Melanoma
Back to Melanoma

Melanoma Trial, Recruiting

NCT06298734
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with melanoma (confirmed by a tissue/biopsy test)
  • You have been receiving immunotherapy for at least one month, or are just starting immunotherapy
  • You are planned to continue immunotherapy for at least 8 weeks from the time you join the study
  • You are reasonably able to carry out everyday physical activities and complete fitness assessments (confirm with trial site)
  • You are able to understand the study and are willing to sign a consent form agreeing to take part

Who may not be able to join:

  • You are currently doing 150 minutes or more of moderate-to-vigorous exercise per week on a regular basis
  • You are eating 30 grams or more of dietary fiber per day on a regular basis
  • You have serious ongoing health conditions that are not well controlled by medication and that could make exercise risky, such as unstable heart problems, uncontrolled diabetes, or bone complications with a risk of fracture
  • You have a history of frequently missing medical appointments (3 or more no-shows in 6 months) or have not responded to multiple contact attempts during recruitment, which may suggest difficulty following the study schedule
  • You do not speak English and are unable to complete the study surveys in English

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dong-Woo Kang, PhD, Fred Hutch/University of Washington Cancer Consortium

Phone: 206-667-5188

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 July 2024
Est. completion
31 July 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Proportion of Participants Completing the Intervention Sessions

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov